Leproust Emily M. sold $444K of TWST
Leproust Emily M. (Chief Executive Officer) sold 6,465 shares of Twist Bioscience Corp (TWST) at $68.61 ($0.44M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider-activity tape but does not, by itself, change Twist’s operating outlook or guidance.
Market read
Traders may monitor whether this sale aligns with prior 10b5-1 activity; absent other catalysts, impact is likely muted.
What to watch
Form 4 doesn’t reveal tax/portfolio-need motives; comparing to prior Form 4 schedules and total insider ownership trend is more informative than the single sale.
Background
SEC Form 4 disclosure reports an officer/director’s transaction in the issuer’s stock; 10b5-1 plans are pre-arranged to trade during set windows.
Ticker impact
Twist Bioscience CEO Emily M. Leproust filed an open-market sale of 6,465 shares for ~$443.6K under a 10b5-1 plan.
Likely limited immediate price impact; any effect would be sentiment-driven and modest.
The filing is a routine Form 4 transaction and explicitly states a pre-arranged 10b5-1 plan, reducing interpretability as new negative information.
Market effects
Minimal; this is company-specific insider activity without stated sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
If the sale size is materially larger than the executive’s recent 10b5-1 cadence, traders may treat it as a mild bearish sentiment input despite the plan.
Key entities
- issuerTwist Bioscience Corp
Subject of the insider sale disclosure (Form 4).
- insiderEmily M. Leproust
CEO and officer/director who sold shares under a 10b5-1 plan.
